Epigenetic therapy of lymphoma using histone deacetylase inhibitors

@article{Cotto2010EpigeneticTO,
  title={Epigenetic therapy of lymphoma using histone deacetylase inhibitors},
  author={Maribel Garc{\'i}a Cotto and Fernando Cabanillas and M. G Guzm{\'a}n Tirado and Mar{\'i}a Victoria Hidalgo Garc{\'i}a and Eileen Pacheco},
  journal={Clinical and Translational Oncology},
  year={2010},
  volume={12},
  pages={401-409}
}
In this study, we reviewed epigenetic therapy of lymphomas using histone deacetylase inhibitors (HDACi), a promising new class of antineoplastic agents. Epigenetic therapy, a new therapeutic concept, consists of the use of HDACi and or DNA methyltransferase inhibitors (DNMTi). We conducted a comprehensive review of the literature for antitumour activity of HDACi and its mechanism of action. HDACi modify the expression of several genes related to cancer development, which can result in… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 79 REFERENCES

A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-Hodgkin’s lymphoma

M Kirschbaum, L Popplewell, P Auayporn
  • A California Cancer Consortium study. ASH Annual Meeting Abstract
  • 2008
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Targeting histones and proteasomes: new strategies for the treatment of lymphoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL

A phase II pilot study of valproic acid in relapsed/refractory chronic lymphocytic leukemia

VR P.Ganesan, R. Kumar
  • ASCO Meeting Abstract
  • 2009
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…